NTRK1 and cancer: This includes gene fusions that have resulted in the approval of tropomyosin receptor kinase (TRK) inhibitors for TRK fusion-positive cancers, regardless of histology [18, 19] or dabrafenib–trametinib combination for solid tumors with BRAF mutations [20].